8-K: MetaVia's DA-1241 Shows Promise in MASH Treatment with Hepatoprotective and Glucose-Regulating Effects

MetaVia Inc. announces positive Phase 2a clinical trial results for DA-1241, demonstrating hepatoprotective and glucose-regulating effects in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).

Summary

• MetaVia Inc. presented data from its Phase 2a clinical trial of DA-1241 at the EASL Congress 2025.
• The trial involved 109 subjects with presumed MASH who received varying doses of DA-1241 or a placebo over 16 weeks.
• DA-1241 demonstrated both hepatoprotective and glucose-regulating effects.
• The 100 mg dose of DA-1241 significantly reduced plasma ALT levels by a mean of 22.8 U/L after 16 weeks.
• The Controlled Attenuation Parameter (CAP) score improved by 23.0 dB/m, indicating reduced liver fat content.
• Improvements in systemic inflammatory and fibrosis biomarkers were also observed.
• DA-1241 also improved glycemic control in patients with comorbid prediabetes and type 2 diabetes.
• The drug was well-tolerated across patient groups, with a favorable safety profile.
• MetaVia plans to review these findings with the FDA in the first half of 2025.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, indicating potential for DA-1241 as a MASH treatment. The favorable safety profile and planned FDA meeting further contribute to a positive outlook.

Positives

• DA-1241 shows promise as a potential treatment for MASH, addressing both liver health and glucose regulation.
• The drug demonstrated a favorable safety profile in the Phase 2a trial.
• DA-1241 improved non-invasive liver assessments such as CAP and FibroScan-AST (FAST) scores.
• The drug's anti-inflammatory and anti-fibrotic actions may drive its hepatoprotective effects.
• DA-1241 efficiently improved glycemic control in patients with comorbid prediabetes and type 2 diabetes.

Risks

• The forward-looking statements are subject to risks and uncertainties, including those associated with MetaVia's ability to execute on its commercial strategy.
• The ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates is not guaranteed.
• Clinical trial results may not be consistent with pre-clinical and previous clinical trials.

Future Outlook

MetaVia plans to continue pre-clinical studies to explore other combination therapies for DA-1241 and intends to review Phase 2 findings with the FDA in the first half of 2025.

Management Comments

• Hyung Heon Kim, President and Chief Executive Officer of MetaVia, stated that DA-1241 is the first oral GPR119 agonist to demonstrate both hepatoprotective and glucose-regulating effects in presumed MASH patients.
• Kim believes that the novel mechanism of action of DA-1241 supports further development as either a monotherapy or combination therapy for MASH and metabolic diseases.

Industry Context

The announcement positions MetaVia as a player in the competitive MASH treatment landscape, where companies are actively developing therapies to address this growing metabolic disease.

Comparison to Industry Standards

• DA-1241's ability to demonstrate both hepatoprotective and glucose-regulating effects in a single agent is notable, as many current MASH therapies focus on only one aspect of the disease.
• Companies like Intercept Pharmaceuticals (OCALIVA) and Madrigal Pharmaceuticals (resmetirom) are also developing MASH treatments, but DA-1241's GPR119 agonist mechanism offers a different approach.
• The observed reduction in ALT levels and improvement in CAP scores are clinically meaningful and compare favorably to results from other Phase 2 trials in the MASH field.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Successful development of DA-1241 could provide a new treatment option for patients with MASH.
• Employees may benefit from the company's progress and potential growth.

Next Steps

• Conduct further pre-clinical studies to explore other combination therapies for DA-1241.
• Review Phase 2 findings at an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in the first half of 2025.

Key Dates

Keywords

MASH, DA-1241, GPR119 agonist, hepatoprotective, glucose-regulating, clinical trial, MetaVia, EASL Congress, metabolic dysfunction, biotechnology